Nutropin HGH is a product that is manufactured by Genentech to help people with Human Growth Hormone (HGH) deficiency. This product is designed in the same manner as the growth hormone produced by the body. When a person uses this product the levels of the growth hormone rises significantly. This is hormone is important to the body because it is the one that determines growth rate. Children who have deficiency of this particular hormone usually grow slower than they should. But once they are injected with this particular product the levels of the human growth hormone in their body rises and they are able to grow in the normal rates.
Nutropin AQ is also helpful to adults especially those who would like to lose weight and gain muscles. This is because it helps in burning fat that is usually stored by the body. The product usually increases the rate of metabolism in the body. This encourages the body to burn the excess fat while building muscles. Because of this the product is very popular among people who participate in activities such as sports. This product is also known to improve the moods of the people who use it. This has a direct result of reducing stress in such people.
home drugs a-z list side effects drug center nutropin (somatropin (rdna origin) for inj) drug
Privacy & Trust Info
[somatropin (rDNA origin)] Injection
Nutropin [somatropin (rDNA origin) for injection] is a human growth hormone (hGH) produced by recombinant DNA technology. Nutropin has 191 amino acid residues and a molecular weight of 22,125 daltons. The amino acid sequence of the product is identical to that of pituitary-derived hGH. Nutropin may contain not more than fifteen percent deamidated GH at expiration. The deamidated form of GH has been extensively characterized and has been shown to be safe and fully active.
Nutropin is a sterile, white lyophilized powder intended for subcutaneous administration after reconstitution with Bacteriostatic Water for Injection, USP (benzyl alcohol preserved). The reconstituted product is nearly isotonic at a concentration of 5 mg/mL GH and has a pH of approximately 7.4.
Each 10 mg Nutropin vial contains 10 mg (approximately 30 IU) somatropin, lyophilized with 90 mg mannitol, 3.4 mg sodium phosphates (0.8 mg sodium phosphate monobasic and 2.6 mg sodium phosphate dibasic), and 3.4 mg glycine.
Bacteriostatic Water for Injection, USP is sterile water containing 0.9 percent benzyl alcohol per mL as an antimicrobial preservative packaged in a multidose vial. The diluent pH is 4.5 – 7.0. [See HOW SUPPLIED/Storage and Handling].
Growth Hormone Deficiency (GHD)
Nutropin® is indicated for the treatment of pediatric patients who have growth failure due to inadequate secretion of endogenous growth hormone (GH).
Growth Failure Secondary to Chronic Kidney Disease (CKD)
Nutropin is indicated for the treatment of growth failure associated with CKD up to the time of renal transplantation. Nutropintherapy should be used in conjunction with optimal management of CKD.
Idiopathic Short Stature (ISS)
Nutropin is indicated for the treatment of ISS, also called non-GHD short stature, defined by height SDS ≤-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means.
Short Stature Associated with Turner Syndrome (TS)
Nutropin is indicated for the treatment of short stature associated with TS.
Nutropin is indicated for the replacement of endogenous GH in adults with GHD who meet eitherof the following two criteria:
Patients who have GHD, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or
Patients who were GH deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes.
Patients who were treated with somatropin for GHD in childhood and whose epiphyses are closed should be reevaluated before continuation of somatropin therapy at the reduced dose level recommended for GH deficient adults. According to current standards, confirmation of the diagnosis of adult GHD in both groups involves an appropriate GH provocative test with two exceptions: (1) patients with multiple pituitary hormone deficiencies due to organic disease; and (2) patients with congenital/genetic GHD.
Digestive Disorders: Common Misconceptions
DOSAGE AND ADMINISTRATION
For subcutaneous injection.
Therapy with Nutropin should be supervised by a physician who is experienced in the diagnosisand management of pediatric patients with short stature associated with growth hormone deficiency(GHD), chronic kidney disease, Turner syndrome, idiopathic short stature, or adult patients with either childhood-onset or adult-onset GHD.
Dosing for Pediatric Patients
Nutropin HGH dosage and administration schedule should be individualized for each patient. Response to growth hormone (GH) therapy in pediatric patients tends to decrease with time. However, in pediatric patients failure to increase growth rate, particularly during the first year of therapy, suggests the need for close assessment of compliance and evaluation of other causes of growth failure, such as hypothyroidism, under-nutrition, advanced bone age and antibodies to recombinant human GH (rhGH).
Treatment with Nutropin HGH for short stature should be discontinued when the epiphyses are fused.
Pediatric Growth Hormone Deficiency (GHD)
A weekly dosage of up to 0.3 mg/kg of body weight divided into daily subcutaneous injection is recommended. In pubertal patients, a weekly dosage of up to 0.7 mg/kg divided daily may be used.
Bertram Meidl –
Yes, this is a Good one